Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics, Inc. develops, manufactures and sells medical technology devices used by professional healthcare providers in vascular disease, oncology and surgical settings. The company’s recurring updates center on its Med Tech portfolio, including AlphaVac and AngioVac mechanical thrombectomy products, Auryon, and the NanoKnife System for irreversible electroporation-based tumor ablation.
Company news also covers fiscal earnings, guidance changes, product adoption, reimbursement and coding topics, FDA clearances and investigational device exemptions, and expanded European indications for NanoKnife across liver, pancreas, kidney and prostate tumors. Other recurring items include pulmonary embolism research initiatives, cardiovascular scientific forums, investor conference presentations and portfolio changes following completed divestitures and discontinued product lines.
AngioDynamics (NASDAQ: ANGO) reported 24‑month data from the pivotal U.S. PRESERVE trial of its NanoKnife IRE System in intermediate-risk prostate cancer. Results showed 0 new treatment failures between 12–24 months, 97% of patients with PSA below baseline, 94.4% 24‑month completion, and no new device- or procedure-related adverse events.
AngioDynamics (NASDAQ: ANGO) reported fiscal Q3 FY2026 net sales of $78.4M (+8.9% pro forma) and Med Tech sales $37.3M (+19%). GAAP net loss was $8.1M (loss per share $0.19); adjusted loss per share was $0.07 and adjusted EBITDA was $1.8M. Cash at quarter end was $37.8M. The company raised FY2026 guidance to $313.5–$315.5M net sales and $10.0–$12.0M adjusted EBITDA, while noting a full‑year tariff impact of $4–$6M and a planned $3–$5M inventory build that may slightly push FY cash flow negative.
AngioDynamics (NASDAQ: ANGO) said its management team will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 8:45 a.m. ET. A live webcast will be available via the company’s Investors website and will be posted for replay after the event.
AngioDynamics (NASDAQ: ANGO) will report fiscal 2026 third quarter results before market open on April 2, 2026. Management will host a conference call at 8:00 AM ET the same day and a live webcast will be available in the Investors section of the company website.
Replay and a recorded telephone playback will be available after the call; the recorded telephone playback is accessible until April 9, 2026 at 11:59 PM ET.
AngioDynamics (NASDAQ: ANGO) announced that President and CEO Jim Clemmer will present at the Leerink Partners Global Healthcare Conference on Monday, Mar. 9, 2026 at 1:40 p.m. ET. A live webcast will be available via the company’s Investors website and a replay will be posted after the event.
AngioDynamics (NASDAQ: ANGO) announced expanded European indications for its NanoKnife System on February 19, 2026, adding soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including intermediate-risk prostate cancer.
The move broadens physician access to NanoKnife's irreversible electroporation (IRE) non-thermal ablation technology and the company will launch the LIVER-IRE Global Registry to collect prospective real-world liver tumor outcomes.
AngioDynamics (NASDAQ: ANGO) and The PERT Consortium launched the ALPHA-PE Research Fund to support investigator-led pulmonary embolism (PE) research. Awards range from $50,000 to $750,000 over one to three years to fund real-world, physician-driven studies addressing PE evidence gaps and patient outcomes.
The program invites Letters of Intent followed by full proposals for selected applicants and is intended to generate clinically relevant real-world evidence to inform PE care.
AngioDynamics (NASDAQ: ANGO) will host its third Cardiovascular Scientific Forum Feb 6–8, 2026, to convene interventional cardiologists, surgeons, and researchers for physician-led collaboration, hands-on workshops, and investigator meetings focused on evidence generation across the cardiovascular portfolio.
Recent regulatory milestones include Nov 2025 FDA IDE approval for the APEX-Return pivotal study (AlphaReturn with AlphaVac F1885, up to 40 patients), Nov 2025 FDA 510(k) clearance for a modified AlphaVac F1885, and Nov 2025 IDE approval for the PAVE pilot (AngioVac, up to 30 patients), building clinical evidence for PE, VTE, and right-heart vegetation removal.
AngioDynamics (NASDAQ: ANGO) reported fiscal Q2 2026 results: net sales $79.4M (+8.8% pro forma) and Med Tech sales $35.7M (+13.0%). GAAP net loss was $6.4M (loss per share $0.15) and adjusted loss per share was $0.00. Adjusted EBITDA was $5.9M and cash was $41.6M.
The company secured three regulatory milestones for its Mechanical Thrombectomy portfolio (APEX-Return IDE, PAVE IDE, modified AlphaVac 510(k)), concluded patent litigation with Bard, and raised FY2026 net sales guidance to $312–$314M and adjusted EBITDA to $8–$10M. CEO Jim Clemmer will retire upon successor appointment expected in fiscal 2027.
AngioDynamics (NASDAQ: ANGO) will report fiscal 2026 second quarter results before the market open on Tuesday, January 6, 2026. Management will host a conference call at 8:00 AM ET the same day to discuss results. Investors can join by dialing 1-877-407-0784 (domestic) or +1-201-689-8560 (international) or via webcast in the company Investors section at www.angiodynamics.com.
A webcast replay will be available about one hour after the call and a recorded playback will be accessible until Tuesday, January 13, 2026 at 11:59 PM ET by dialing 1-844-512-2921 (domestic) or +1-412-317-6671 (international) using passcode 13757614.